MAPT and Alzheimer disease: Similarly, the phase II TANGO trial (NCT03352557) in patients with MCI or mild AD reported no significant benefits on clinical endpoints, including CDR-SB or tau-PET after 78 weeks of monthly infusions at three different doses.